Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Men,,Tablet,And,Barista,With,Pride,,Small,Business,And,Colleagues

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Small Business

Tech

ETFs

CRDF

CRVO

GOEV

NRDY

SCLX

UNFI

Small businesses are entering the holiday season with newfound confidence and momentum, thanks to post-election policies and reduced inflation.

US Small Business Optimism Hits 3-Year High As Election Results &#39;Signal A Major Shift&#39;

Biotech

News

Health Care

Movers

General

Cardiff Oncology&#39;s CRDF-004 trial shows promising onvansertib results in RAS-mutated mCRC patients, with higher tumor response rates and a strong safety profile.

What&#39;s Going On With Cardiff Oncology Stock On Tuesday?

Earnings

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

BCDA

BIVI

DECK

JOAN

QNRX

RNLX

SMCI

ZION

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 edging lower on Monday.

The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&amp;P 500 also fell, dropping, 0.01% to 5,137.05.

Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher

Cardiff Oncology Inc

WIIM

AVGO

Broadcom and Micron Technology shares are trading higher after Broadcom announced the availability of its end-to-end PCIe Gen 6 portfolio and a partnership for the expansion of AI infrastructure.

Stifel analyst Stephen Gengaro maintains DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) with a Hold and raises the price target from $8 to $9.5.

Price Target

Analyst Ratings

BOOM

Stifel Maintains Hold on DMC Glb, Raises Price Target to $9.5

EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) has outperformed the market over the past 20 years by 10.28% on an annualized basis producing an average annual return of 18.48%. Currently, EQT has a market capitalization of $29.39 billion. 
Buying $1000 In EQT: If an investor had bought $1000 of EQT stock 20 years ago, it would be worth $29,724.38 today based on a price of $49.20 for EQT at the time of writing.
<h3>EQT's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740579310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning EQT Stock In The Last 20 Years

Wells Fargo analyst Matthew Akers maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Equal-Weight and lowers the price target from $497 to $468.

Wells Fargo Maintains Equal-Weight on Lockheed Martin, Lowers Price Target to $468

AVNS

Avanos Medical shares are trading lower after the company issued FY25 sales and FY25 Adj EPS guidance below estimates.

Wells Fargo analyst Matthew Akers maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Overweight and lowers the price target from $300 to $269.

Wells Fargo Maintains Overweight on L3Harris Technologies, Lowers Price Target to $269

Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) stock is trading higher in the premarket session on Wednesday after the company reported better-than-expected<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43967530/lowes-reports-fourth-quarter-2024-sales-and-earnings-results" rel="noreferrer noopener"> fourth-quarter earnings</a>.
The company reported adjusted earnings per share of $1.93 above the street view of $1.84.
Quarterly sales were $18.553 billion, a slight decline of 0.3% year over year, but they outpaced the analyst consensus estimate of $18.292 billion.
Comparable sales for the quarter increased 0.2%, driven by Pro, online growth, holiday sales and hurricane recovery, offset by weak DIY discretionary spending.
Related: <a target="_blank" href="https://www.benzinga.com/25/02/43964363/lowes-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call" rel="noreferrer noopener">Lowe&#8217;s Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
The quarter&#8217;s gross margin expanded slightly by 50 bps year over year to 32.9%. Quarterly operating income totaled $1.83 billion compared with $1.687 billion a year ago, with a margin up 80 bps to 9.9%.
As of Jan. 31, 2025, Lowe&#8217;s operated 1,748 stores, representing 195.0 million square feet of retail selling space.
The company prioritized capital allocation, repurchasing 5.5 million shares for $1.4 billion and paying $650 million in dividends this quarter, totaling $6.5 billion returned to shareholders for fiscal 2024.
&#8220;We remain confident in the long-term strength of the home improvement industry, and we are equally confident in our strategy to capitalize on the expected recovery. We are also pleased to award $80 million in discretionary bonuses to our frontline associates in recognition of their hard work and dedication to delivering excellent customer service,&#8221; said Marvin R. Ellison, Lowe&#8217;s chairman, president and CEO.
The company&#8217;s net cash provided by operating activities for 2024 totaled $9.625 billion, up from $8.140 billion a year ago.
2025 Outlook: Lowe&#8217;s forecasts 2025 EPS of $12.15–$12.40, below the $12.51 consensus estimate. Total sales are projected at $83.5 billion &#8211; $84.5 billion, compared to the $84.56 billion consensus.
The company expects an operating margin of 12.3%–12.4% and plans approximately $2.5 billion in capital expenditures.
Price Action: LOW shares are trading higher by 3.64% to $251.21 premarket at last check Wednesday.
Read Next: <a href="https://www.benzinga.com/government/regulations/25/02/43967649/us-stocks-likely-to-open-higher-ahead-of-nvidia-earnings-sp-500s-four-day-fall-was-a-non-event-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&amp;P 500&#8217;s Four-Day Fall Was A &#8216;Non-Event,&#8217; Says Expert</a>
Photo: Shutterstock

Guidance

Retail Sales

Lowe's Q4 Win: Higher Profits, Big Buybacks And A Cautious 2025 Outlook

Stephens &amp; Co. analyst Mike Scialla maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Overweight and raises the price target from $43 to $44.

Stephens & Co. Maintains Overweight on Range Resources, Raises Price Target to $44

Stifel analyst Craig Jones maintains Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) with a Hold and raises the price target from $2 to $3.

Stifel Maintains Hold on Agilon Health, Raises Price Target to $3

Agilon Health shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

Wells Fargo analyst Matthew Akers maintains General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) with a Equal-Weight and lowers the price target from $276 to $244.

Wells Fargo Maintains Equal-Weight on General Dynamics, Lowers Price Target to $244

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading around our key level of 596.57. Bulls need to maintain support above this level to drive the price higher toward 598.04. If buyers sustain momentum above 598.04, we anticipate a move toward 599.24, which should act as an area of strong support. Continued buying pressure could propel SPY toward 600.51, with the potential for an extended rally to our high bull target of 601.22.
Should 596.57 fail to hold as support, sellers are likely to push SPY down to 595.14. A breakdown of this level could invite further downside action, with 593.73 as the next key area of interest. If selling intensifies and 593.73 is breached, we expect a test of solid support at 592.00. In an aggressive sell-off scenario, SPY could reach our low bear target of 589.71.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is trading around our pivotal level of 517.97. Bulls need to establish control above 518.65 to gain momentum, with the next upside level at 519.87 acting as a potential springboard for higher prices. If buyers sustain pressure, we could see a push toward 521.15. A strong bullish session would likely bring 522.57 into play, with our high bull target set at 523.91.
Failure to maintain support above 517.97 opens the door for a move lower to 516.58. If weakness persists, sellers could drive QQQ toward 515.00, which serves as a key support zone. A breakdown below this level could accelerate selling pressure, leading to a test of 513.64. If bearish momentum is strong, we anticipate a move down to our low bear target of 511.53.
Apple Inc. (AAPL)
Apple is currently trading near 245.58, a critical level to hold for buyers. If bulls defend this area, we could see an initial push to 246.72. A sustained rally above this level may lead to a move toward 248.12, where bulls will aim to establish strong support. Should the uptrend remain intact, AAPL has the potential to reach our high bull target of 249.04.
If 245.58 fails as support, sellers are likely to test 244.45 to the downside. A break below this level could trigger further selling pressure, bringing 243.57 into play. If the downtrend continues, Apple could test 242.83 as another key area of support. A sharp sell-off may see the price reach our low bear target of 242.21.
Microsoft Corp. (MSFT)
Microsoft is currently trading around 400.30, with bulls needing to maintain this level for further upside potential. If buyers take control, we expect a move toward 401.39, where holding above this level would strengthen the case for a rally to 402.74. If demand persists, the price could climb toward our high bull target of 404.92.
If 400.30 does not hold as support, bears will look to test 399.21. A breakdown here could push the price lower to 398.38, potentially leading to increased selling pressure. If sellers remain aggressive, we anticipate a move toward 397.65. Should downside momentum continue, Microsoft could reach our low bear target of 395.68.
NVIDIA Corporation (NVDA) NVIDIA is currently trading around 129.53. Bulls need to sustain momentum above this level to target 131.42 as the next key resistance. If buyers maintain control, we could see a push to 132.19, with the potential for an extended rally to 133.31. A strong bullish session may allow NVDA to reach our high bull target of 134.56.
If 129.53 fails to hold as support, bears will look to push the price lower to 128.10. Breaking this level could see NVDA testing 126.84 as another key downside level. Further weakness in the auction may lead to a move toward 125.21. If selling pressure remains strong, the stock could fall to our low bear target of 123.41.
Alphabet Inc Class A (GOOGL)
Alphabet is currently trading near 177.28, with bulls needing to maintain this level to sustain upward momentum. If buyers step in, we expect a push toward 179.15. A breakout above this level could lead to further upside, with a potential move toward our high bull target of 180.46.
If 177.28 fails to act as support, bears will look to drive the price lower to 176.23. If this level is lost, we anticipate a test of 175.12. Continued bearish action could send the stock further down to our low bear target of 174.01.
Meta Platforms Inc (META)
Meta is currently auctioning near 663.33, an important level for bulls to defend. If buyers can keep the price above this level, we anticipate a move to 667.99. Continued strength in the auction could push META to 671.80, with potential upside extending to our high bull target of 676.46.
Should 663.33 fail to hold as support, we expect bears to take control and drive the price lower to 658.86. A breakdown below this level could open the door to further downside, testing 655.54. If selling pressure remains dominant, META could trade down to our low bear target of 650.56.
Tesla Inc. (TSLA)
Tesla is currently trading around 310.17, with bulls needing to sustain momentum above this level for further upside. If buyers step in, we expect a move toward 312.42. A breakout above this level could set the stage for a rally to 315.93. If bullish momentum remains strong, Tesla may test our high bull target of 327.59.
If 310.17 is lost as support, bears will likely push the price lower to 304.24. A breakdown here could bring 300.56 into play as a critical support level. If selling intensifies, we anticipate further downside movement toward our low bear target of 298.28.
Final Word:
Today&#8217;s market session lacks major economic catalysts, leaving technical levels and overall market sentiment as the key driving forces. The most notable data release comes at 10 AM ET with January's New Home Sales report. Additionally, at 11:30 AM ET, the Treasury will conduct a 2-year FRN auction, followed by a 7-year FRN auction at 1 PM ET. These events could introduce some volatility in the bond market, but overall, traders should focus on price action and key levels.
One of the most significant market events today will be NVIDIA&#8217;s earnings report after the close, which has the potential to drive major movement in the semiconductor sector and broader market sentiment. Given the market&#8217;s heavy reliance on tech stocks, particularly NVDA, any surprises in their report could lead to increased volatility. Stay disciplined, manage risk effectively, and be prepared for potential market reactions after-hours. Trade smart!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Technicals

Pre-Market Outlook

No Major Economic Catalysts Today; Nvidia's Earnings In Focus

Stephens &amp; Co. analyst Daniel Imbro maintains Matson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) with a Overweight and raises the price target from $165 to $175.

MATX

Stephens & Co. Maintains Overweight on Matson, Raises Price Target to $175

Stifel analyst David Grossman maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Buy and lowers the price target from $390 to $380.

Stifel Maintains Buy on Accenture, Lowers Price Target to $380

NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) today announced the successful completion of lab and field demonstrations of its innovative Positioning, Navigation, and Timing (PNT) solution based on Positioning Reference Signal (PRS) standards in 5G waveforms. With 5G and PRS standards already in place, this validates that NextNav PNT technology solutions can enable a widescale commercial 5G-based PNT solution that provides a resilient terrestrial complement and backup to traditional GPS signals.
The demonstrations culminated in a successful field test using a prototype network operating on NextNav's existing spectrum in Palo Alto, California. These tests validated the effectiveness of NextNav's 5G PRS-based PNT solution, demonstrating precise timing synchronization and robust positioning capabilities, establishing a foundation for widespread commercial deployment.

NextNav Announces Completion Of 5G-Based PNT Solution Demos, Validates Commercial Potential As GPS Backup With Successful Palo Alto Field Tests

Wells Fargo analyst Vik Chopra maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $193 to $205.

MASI

Wells Fargo Maintains Overweight on Masimo, Raises Price Target to $205

TJX Companies shares are trading higher after the company reported better-than-expected Q4 financial results.

Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) with a Equal-Weight and lowers the price target from $40 to $35.

RXST

Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $35

USNA

Usana Health Sciences shares are trading higher after the company reported better-than-expected Q4 financial results.

CNSP

CNS Pharmaceuticals Announces Plans For TPI 287 Clinical Program Launch By Year-End; Primary Data Analysis For Berubicin Expected In H1 2025

Press Releases

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

Legal

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Financing

IPOs

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Stocks to Watch in December 2025: LDTC, CPIX, PNPN.V, ZEO, and More Inside

Opinion

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Comments

Cardiff Oncology

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga